Acarbose versus trans-chalcone: comparing the effect of two glycosidase inhibitors on obese mice

Fatemeh Jalalvand1, Mahsa M Amoli2, Parichehreh Yaghmaei1

  • 1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Abstract

Insights

Acarbose and trans-chalcone show potential in managing obesity by influencing lipid accumulation and adipokines. These glucosidase inhibitors may help reduce inflammation and oxidative stress in obese mice.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Acarbose and trans-chalcone are known glucosidase inhibitors with established benefits in diabetes management.
  • Obesity is a complex metabolic disorder associated with inflammation and oxidative stress.

Purpose of the Study:

  • To investigate the potential anti-obesity effects of acarbose and trans-chalcone.
  • To evaluate their impact on biochemical parameters, adipokines, and tissue histology in diet-induced obese mice.

Main Methods:

  • Male NMRI mice were fed a high-fat diet to induce obesity, then treated with acarbose or trans-chalcone (12 mg/kg) for eight weeks.
  • Measurements included body weight, blood glucose, lipid profiles (triglycerides, cholesterol, HDL), liver enzymes (AST, ALT), adipokines (leptin, adiponectin), TNF-α, and total antioxidant capacity (TAC).
  • Histological analysis of adipose tissue and liver was performed.

Main Results:

  • Acarbose showed positive trends but not statistically significant effects on body weight, blood sugar, and leptin.
  • Trans-chalcone significantly impacted HDL, leptin, and ALT levels.
  • Grape seed oil (trans-chalcone solvent) improved triglycerides and TAC, with beneficial effects on liver enzymes and cholesterol.
  • Both compounds appeared to reduce fat deposition in the liver and decrease adipocyte size.

Conclusions:

  • Acarbose and trans-chalcone can influence lipid accumulation and adipokine levels in obese mice.
  • These effects suggest a potential role in mitigating inflammation and oxidative stress associated with obesity.
  • Further research is warranted to explore their therapeutic applications in obesity management.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
893
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
966
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
399